source
- BridgeBio secures up to $1 billion in preferred equity as United Therapeutics invests $140 million to acquire ThymmuneBridgeBio Pharma announced that Sixth Street Partners and HealthCare Royalty will provide up to $1 billion in preferred equity to support its upcoming product launches. The financing is structured…
- Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M dealThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.BioPharma Dive · 1mo ago↗ source